Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial.

The nonparametric mITT-LOCF analysis demonstrated a highly significant, medium to large superiority of Cerebrolysin relative to placebo from day 7 onwards, peaking at day 30, with an MW equal to 0.66 (95% CI: 0.55-0.78; P=0.005; Fig. 2 ).

also in 132,142 other papers

Effect sizes in the MMSE and PGS did not reach statistical significance.

also in 111,027 other papers